ArticlePharmaceutics2022
Design-of-Experiments (DoE)-Assisted Fabrication of Quercetin-Loaded Nanoemulgel and Its Evaluation against Human Skin Cancer Cell Lines.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Development and optimization of 6-Hydroxyflavone-loaded nanoemulgel for enhanced topical anti-inflammatory activity.Inflammopharmacology · 2026Article
- Targeting Skin Cancer with Natural Bioactive Compounds: From Molecular Mechanisms to Application Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Przewaquinone A regulates cell cycle and autophagy through the SrC/STAT3 signaling pathway to inhibit colorectal cancer progression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Quercetin and Its Nano-Based Formulations Against Skin Cancer: A Narrative Review.Health science reports · 2026Article
- Nanoemulgels as Advanced Topical Drug Delivery Systems: Mechanistic Insights and Therapeutic Applications in Skin Disorders, Infections, Wound Healing, and Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Transcutaneous Delivery of Dual-Approach Oxaprozin and Apricot Kernel Oil Through a QbD Driven Nanoemulgel: Therapeutic Potential Against Osteoarthritis-Induced Animal Model.Pharmaceutical research · 2026Article
- Reactive oxygen species in skin diseases: pathogenic mechanisms and nanomaterial-based therapeutic strategies.Frontiers in bioengineering and biotechnology · 2026Review
- Development andNanomedicine (London, England) · 2025Article
- Nanoemulsions in Skin Cancer Therapy: A Promising Frontier.Current pharmaceutical biotechnology · 2025Review
- Quercetin Nano-formulations as a Potential Approach for Skin Cancer.Pharmaceutical nanotechnology · 2025Review
- Natural Compounds in Non-Melanoma Skin Cancer: Prevention and Treatment.Molecules (Basel, Switzerland) · 2024Review
- Development and evaluation of berberine-loaded bigel for the treatment of hyperpigmentation on B16F10 melanoma cell line.Nanomedicine (London, England) · 2024Article
- An Overview of Nanoemulgels for Bioavailability Enhancement in Inflammatory Conditions via Topical Delivery.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.